Rigel Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML

/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced promising data from an analysis of the Phase 2 study evaluating REZLIDHIA®...

Related Keywords

United States ,California ,Georgia ,South San Francisco ,American ,Jorgee Cortes ,Cecilf Whitaker Jr ,David Rosen ,Raul Rodriguez ,Exchange Commission ,Drug Administration ,American Cancer Society ,Georgia Cancer Center ,Nasdaq ,European Hematology Association ,Prnewswire Rigel Pharmaceuticals Inc ,Rigel Pharmaceuticals Inc ,Scholar Chair ,Post Venetoclax Patients ,Practice Guidelines ,Full Prescribing Information ,Rigel Pharmaceuticals ,American Cancer ,Key Statistics ,Acute Myeloid Leukemia ,Revised January ,Acute Myeloid Leukaemia ,Quarterly Report ,Nc ,